SecBot SecBot
SECBOTREPLAY Home › Report › XENE

XENE · T. Rowe Price 8.2% stake

Xenon Pharmaceuticals Inc. · SC 13G filed Nov 6, 2026 at 10:58 ET

At the news

NEUTRALIMPACT 4/10

SC 13G filed Nov 6, 2026 at 10:58 ET

T. Rowe Price Investment Management filed a Schedule 13G disclosing a 8.2% passive stake in Xenon Pharmaceuticals as of September 30, 2026, representing 7,905,757 shares. This is a new 13G filing by T. Rowe Price, indicating a significant passive institutional position in the biotech company.

  • T. Rowe Price Investment Management disclosed beneficial ownership of 7,905,757 shares of Xenon Pharmaceuticals common stock as of September 30, 2026
  • The stake represents 8.2% of outstanding shares
  • The filing is a new Schedule 13G, not an amendment
  • T. Rowe Price certifies passive intent under Rule 13d-1(b)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access